# NCT03330847 (NCT03330847)

> To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03330847
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Metastatic Triple Negative Breast Cancer
- Interventions: Olaparib Continuous (28-Day cycle) 300 mg BD.; Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).; Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).
- Enrollment: 273
- Primary outcome: Progression-free Survival Per Stratum (BICR)
- Primary outcome: Progression-free Survival Per Stratum (Sensitivity Analysis)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03330847